INSIGHTS ON DRUG DISCOVERY

• Preclinical Technique To Assess Targeted Therapies For Primary, Metastatic NSCLC

  To enable comprehensive evaluation of therapies targeting both primary and metastatic tumors, we've developed dual-disease xenograft models using bioluminescence imaging (BLI).

• Unlock The 3 Keys To Drug Discovery Success — Foresight, Hindsight, And Insight

  If you don’t know where you are going, how will you get there? Articulating the destination of your therapeutic is essential for determining whether it is commercially viable and meets required milestones.

• Phenotypic Characterization Of Bleomycin-Induced Pulmonary Fibrosis Mod

  To gain deeper biological insight, lung injury in this model has been further characterized through cellular phenotyping, gene expression analysis, and cytokine profiling.

• Decoding The Conformational Plasticity Of Ternary Complexes For Protacs' Differential Activity

  Leverage our insights into PROTAC ternary complex plasticity and stability to accelerate the design of next-generation therapeutics.

• Scalable Production Of High-Purity Nanobodies Using Yeast Expression System

  9/8/2025

  Leverage scalable K. pastoris expression systems to produce high-quality nanobodies for cutting-edge therapeutic, diagnostic, and research applications.

• Streptozotocin-Induced Diabetic Peripheral Neuropathic Pain Model

  9/8/2025

  Emerging research highlights that insulin deficiency drives sensory neuropathy, and early insulin therapy may help prevent or alleviate chronic diabetic neuropathic pain.

• NIH:OVCAR-3 Human Ovarian Cancer Model

  8/26/2025

  Review studies using the NIH:OVCAR-3 model of human ovarian cancer in the subcutaneous setting in NSG mice with multiple standard agents and vehicles. This model has shown reproducible growth.

• An Alternative Genetic Engineering Tool In CHO Cells

  8/15/2025

  Discover how transposon technology is being reimagined as a precise genetic engineering tool to create high-performing CHO cell lines for biotherapeutic production with enhanced metabolic and glycan profiles.

• Designing IND-Enabling Toxicity Studies For Complex Drug Modalities

  8/6/2025

  Learn more about how we adapt and enhance conventional small molecule IND-enabling studies to align with the evolving demands of modern therapeutics.